Enzyme kinetic studies from this laboratory (M. Dobersen and S. Greer, Biochemistry 17:920-928, 1978) suggested that deoxycytidine could antagonize the toxicity of 5-halogenated analogs of deoxycytidine without interfering with their antiviral activity. Antagonism by deoxycytidine of the toxicity of 5-chlorodeoxycytidine without impairing its anti-herpes simplex virus type 2 activity is demonstrated in the present studies. Tetrahydrouridine, an inhibitor of cytidine deaminase, was utilized. The high Km for deoxycytidine (0.6 mM) with respect to the herpes pyrimidine nucleoside kinase as compared with the low Km for 5-chlorodeoxycytidine (1.1 ,uM) accounts for the absence of antagonism of the antiviral activity. The high Km for 5-chlorodeoxycytidine (56 ,uM) as compared with the low Km of deoxycytidine (2 FM) with respect to mammalian deoxycytidine kinase accounts, in great part, for the antagonism of toxicity. In addition, antagonism of toxicity by deoxycytidine is the result of factors other than the kinetic parameters of nucleoside kinases, as indicated by its antagonism of the cytotoxicity of 5-chlorodeoxyuridine. This may be attributed to replenishment of low dCTP pools, diminished because of effector inhibition of ribonucleoside diphosphate reductase by Cl-dUTP. Resistance of the herpes-encoded enzymes to effector control may also play a role in the selective antagonism. Cell culture studies with high concentrations of tetrahydrouridine and 2'-deoxytetrahydrouridine suggest that competition by deoxycytidine for deaminases may not play a major role. The fact that deoxycytidine antagonizes the toxicity of chlorodeoxyuridine also argues against competition for the deaminases as a major reason for its effect. Limited studies with a topical herpes simplex virus type 2 infection system indicate heightened efficacy of 5-chlorodeoxycytidine (and tetrahydrouridine) when deoxycytidine is coadministered. The concepts of selective antagonism of a chemotherapeutic agent derived from these studies may be applied to other approaches that extend beyond viral chemotherapy.
Since the discovery in this laboratory (15) of the broad substrate specificity of the herpes pyrimidine nucleoside kinase, a variety of agents have been examined (3, 7, 8, 18, 19, 22, 23, 27, 41, 43) that are anabolized, preferentially in infected cells, by the viral enzyme to inhibit viral replication and infectivity. We have focused on kinetic studies of host and viral nucleoside kinases (16, 20, 21) and have considered other differences between host and virus regarding metabolism and effector control to elucidate the biochemical mechanisms of the cytotoxic and antiviral effects of 5-halogenated analogs of t Present address: Roche Institute for Molecular Biology, Nutley, NJ 07110. deoxycytidine to discover those manipulations which will maximize the selectivity of these agents. Accordingly, in in vitro and in vivo studies, we have developed principles involving: (i) selective antagonism of cytotoxicity of 5-halogenated pyrimidine analogs by coadministration of deoxycytidine plus tetrahydrouridine, an inhibitor of cytidine deaminase (5, 14, 24, 35) , ( ii) selective rescue of virus-infected, treated animals by delayed administration of thymidine and more effective prevention of deamination of 5-halogenated analogs of deoxycytidine achieved by either (iii) coadministration of 2'-deoxytetrahydrouridine, an inhibitor of both cytidine and dCMP deaminase (32, 33) , or (iv) 4 N alkyl substitution of these analogs. These ma-nipulations superimpose further selectivity on a strategy in antiviral therapy that is intrinsically highly specific. These approaches towards greater efficacy were derived from the thesis studies of L. Fox (L. M. Fox, Ph.D. thesis, University of Miami, Florida, 1979) . The first of these principles, that of selective antagonism of cytotoxicity of 5-chlorodeoxycytidine by deoxycytidine, is the subject of this paper.
Prompted by the findings of earlier studies in our laboratories by Cooper and Greer (16) , Dobersen et al. (21) , and Dobersen and Greer (20) on the kinetic parameters of nucleoside kinases of virus-infected and uninfected cells, we undertook the present investigation. The competition kinetics suggested that inhibition of herpesvirus by 5-halogenated analogs of deoxycytidine would not be antagonized by deoxycytidine because of the extremely high Km (0.6 mM) for deoxycytidine with the herpes pyrimidine nucleoside kinase; in contrast, 5-chlorodeoxycytidine and bromodeoxycytidine have low Kms for this enzyme (1.1 and 1.3 ,M, respectively, for herpes simplex virus type 2 [20] ). The Kms for deoxycytidine and bromodeoxycytidine for the pyrimidine nucleoside kinase of varicella-zoster virus were found to be 61 and 8.5 ,M, respectively (21) . Conversely, we have shown (16) that the 5-Cl, -Br, and -I analogs of deoxycytidine possess very high Kms for the deoxycyticline kinase from mammalian cells (56, 417 , and 1,000 ,M, respectively), in contrast to a low Km for deoxycytidine (2 ,uM) . These kinetic parameters and the associated competition kinetic studies are compelling findings that form the basis of the present study on selective antagonism.
While we were awaiting an initially problematical custom synthesis of sufficient 5-chlorodeoxycytidine for in vivo animal infection experiments which we thought to be appropriate to combine with our cell culture studies, Cheng et al. (10) reported the selective reversal of the cytotoxicity of E-5-propenyl-2'-deoxyuridine, an antiherpetic agent, by thymidine, and Lopez et al. (31) mentioned the antagonism of the toxicity of the antiherpetic agent 2'-fluoro-5-iodo-aracytosine by deoxycytidine, both limited to cell culture studies. In the latter case, cell culture data on antagonism was not shown. Recently, the proceedings of a symposium held in Hamburg, Germany, were published in which data on selective antagonism in cell culture studies were included (22a) .
In addition to the Km considerations, important metabolic factors and differential effector sensitivities of host and viral enzymes may contribute substantially to our achievement of selective antagonism. Specifically, we speculate that cytotoxicity may be primarily based on effector inhibition of ribonucleoside diphosphate reductase leading to starvation for deoxycytidine, whereas viral inhibition is based on incorporation of the 5-halodeoxyuridine derivative into viral DNA, which is not antagonized by deoxycytidine. We speculate further that the host nucleoside diphosphate reductase is sensitive to inhibition by TTP, and especially, 5-bromo-and 5-chloro-dUTP, whereas the viral enzyme is resistant to these effectors. The concept of exploiting differential enzyme kinetic parameters, differential metabolism, and effector sensitivities to obtain selective antagonism with the goal of increased efficacy in chemotherapy may have applications well beyond the area of viral chemotherapy.
MATERIALS AND METHODS Abbreviations. The following abbreviations will be used throughout this paper: dC, deoxycytidine; CldC, 5-chlorodeoxycytidine; BrdC, 5-bromodeoxycytidine; IdC, 5-iododeoxycytidine; dU, deoxyuridine; CldU, 5-chlorodeoxyuridine; BrdU, 5-bromodeoxyuridine; dT, deoxyribosylthymine; dG, deoxyguanosine; CldCTP, 5-chlorodeoxycytidine triphosphate; CldUTP, 5-chlorodeoxyuridine triphosphate; BrdUTP, 5-bromodeoxyuridine triphosphate; H4U, tetrahydrouridine; 2'-dH4U, 2'-deoxytetrahydrouridine; 2'-dH4UMP, 2'-deoxytetrahydrouridine monophosphate; HSV-1 and -2, herpes simplex virus types 1 and 2, respectively; and PBS, phosphate-buffered saline.
Cell culture. HEp-2 cells obtained from the American Type Culture Collection were maintained in Eagle minimal essential medium supplemented with 10%o (vol/vol) virus-screened fetal calf serum, 0.02 ,ug of amphotericin B per ml, 100 U of penicillin per ml, 100 ,g of streptomycin per ml, and 0.015% (wt/vol) sodium bicarbonate (growth medium) at 37°C in a humidified 95% air-5% CO2 atmosphere. Media, sera, and antibiotics were purchased from GIBCO Laboratories International Scientific Industries, K-C Biologicals, and North American Biologicals, Inc Fig. 4 were obtained from the cells utilized in experiment 1. b The concentrations of dC, when used, were 0.3, 0.06, and 0.15 mM in experiments 1, 2, and 3, respectively. in 4 ml of growth medium and allowed to attach overnight. Medium was then replaced with growth medium containing nucleosides or analogs or both. After 48 h of incubation, cells were harvested by trypsinization, serially diluted and replated in growth medium in 60-mm dishes, and incubated for 7 to 9 days. Dishes were then washed twice with PBS solution and stained with crystal violet. Colonies of 50 to 100 cells were counted as one viable original cell with a dissecting microscope. Percent survival was calculated as the average number of colonies glcown out from analog-treated cells divided by untreated controls.
Antiviral assay. Dishes (60 mm) containing confluent monolayers of HEp-2 cells were infected at a multiplicity of infection of 0.05 with virus inoculum in 0.2 ml of medium per plate. Adsorption was allowed to proceed at 370C for 2 h, with agitation every 15 min. Medium containing analogs was then added, and dishes were incubated for 48 h. Virus was harvested by three cycles of freezing and thawing in the dish, scraping, and sonication (30 s). Titration was performed as described above, and titers were expressed as loglo of the surviving fraction relative to untreated controls.
Flow cytometry. Of the cells from the original plates passed in serial dilution for the cytotoxicity assay (Table 1 , experiment 1), 90%o were retained, washed twice with PBS, and suspended in a solution of 5 mg of propidium iodide per 100 ml of 0.1% sodium citrate in distilled water. The cells burst, and intact nuclei bound propidium iodide in proportion to their DNA contents. Nuclei were suspended in 0.1% citrate at a concentration of approximately 106 cells per ml and passed through a flow cytometer (TPS-1; Coulter Electronics, Inc.). The number of nuclei having a given amount of laser-excited fluorescence (hence proportional to DNA per cell) was computer-graphed as a smoothed DNA histogram.
Topical Infection system. Fourteen-week-old hairless mice weighing 21 g each and obtained from Jackson Laboratories were inoculated subcutaneously on one flank with 106 PFU of HSV-2 (about 20 50% lethal doses) in 0.1 ml of PBS. The mice were treated once a day for 8 days as indicated in Results. About 2 to 3 days after inoculation, a point lesion appeared at the site of injection which spread unilaterally to the spine. Death followed a few days later (about 12 days postinfection), with recovery of virus from the skin and brain. Drug solutions were sterile filtered and administered Intraperitoneally in 0.5 to 1.0 ml of PBS. H4U, when used, was administered 30 min before the analogs. Animals were provided food and water ad libidum. The antiviral effect was graded by two methods: the percent survivors in each group daily and the percent maximum number of points, based on severity of symptoms, in each group daily. The point system was arbitrarily established as follows: 6, healthy; 5, point lesion; 4, starting to spread; 3, spreading; 2, extensive; 1, very extensive.
RESULTS
Effect of CldC with or without dC on colonyforming ability. The cytotoxicity of CldC was determined at various concentrations, with and without H4U and dC. The cytidine deaminase inhibitor provided considerable protection to the HEp-2 cells, and the combination with dC resulted in even less toxicity (Fig. 1) .
To determine whether the antagonism that resulted from the addition of dC ( Fig. 1 ) was due to enhanced inhibition of the deamination of CldC to CldU mainly via competition by dC, the concentration of H4U was increased While the CldC and dC concentrations were held constant. If the protection by dC was simply due to its competition for cytidine deaminase, saturati'ng levels of H4U would be expected to eliminate or markedly decrease this protection; however, this was not the case (Fig. 2) . The fraction of surviving cells incubated in the presence of dC continued to remain higher than those without dC when the H4U concentrations were increased. It should be noted that H4U is an intermediate-state analog having an affinity for cytidine deaminase that is 104 times greater than the substrate dC (14) . Although studies with cytidine deaminase-deficient mutant cells would provide data that could be interpreted more directly, the results indicate that competition by dC for cytidine deaminase is not a major mechanism of antagonism. In separate studies, H4U alone, at a concentration of 2,000 ,ug/ml, resulted in 90%o survival, and no decrease in survival was obtained with 1,000 ,ug/ml. dC was not toxic alone and displayed no effect on the survival obtained with H4U.
It is likely that a portion of the antagonism by dC in the presence of H4U is derived from conversion of dCMP, via dCMP deaminase, to dUMP, which is then anabolized to TMP. It was of interest, therefore, to utilize 2'-dH4U, an inhibitor of both cytidine deaminase and dCMP deaminase. The effect of dC on the cytotoxicity of CldC in the presence of several concentrations of 2'-dH4U is shown in Fig. 3 dH4U alone at concentrations of 2,000, 1,000, 500, and 100 ,ug/ml was 72, 86, 92, and 100lo, respectively. dC had no effect on the survival of cells grown in 2'-dH4U.
The antagonism exerted by dC may be the result of competition at several enzymatic levels, including the dC kinase, nucleotide extent of incorporation of CldU and CldC into DNA and the levels and character of deoxyribonucleotide metabolites, including 2'-dH4UMP, in the presence of deaminase inhibitors as well as studies with dCMP deaminase-deficient mutants are planned or in progress.
Effect of CldU and dC on survival and cell cycle kinetics. To further our examination of the mode of antagonism by dC of the cytotoxic effects of CldC, we utilized the chlorinated pyrimidine deoxyribonucleoside analog lacking the 4-NH2 group, CldU. Obviously not a substrate for the deaminase, CldU is anabolized by dT kinase, not dC kinase. Therefore, protection by dC could not be due to competition for dC kinase or the deaminating enzymes. Since dC could compete for dT kinase if deaminated to dU, H4U was always included in incubations to inhibit cytidine deaminase activity. Antagonism of CldU toxicity by dC in the absence of any deaminase inhibitor (Table 1) is likely because of conversion of dC to TMP and anabolism to TTP. dC (in the presence of H4U) did reverse the cytotoxicity of a low concentration of CldU, although it did not protect against the cytotoxic effect of high concentrations of the analog (Table 1, h. Isolated nuclei were stained with propidium iodide, and the DNA histogram was generated by computerassisted flow cytometry.
kinetics was examined at each concentration of CldU (Table 1, experiment 1) . A portion of the cells diluted to assay colony-forming ability was treated immediately to yield the DNA histograms shown in Fig. 4A and B. The cell population incubated with 0.015 mM CldU (Fig. 4A ) displayed a premitotic arrest that was almost completely reversed by dC. This is in agreement with the observed colony-forming ability of this population. However, although no effect of dC was revealed on the colony-forming ability of cells incubated with 0.3 mM CldU and with or without dC, an occult dC effect became apparent in the cell cycle kinetics of this population (Fig.  4B) . Almost the entire population was arrested in G-1 phase by CldU. Addition of dC to the incubation allowed the population to continue the cycle to a premitotic arrest point slightly to the left of the G-2 peak of the control cells. This inability of the population to complete the cell cycle explains the apparent ineffectiveness of dC VOL. 22, 1982 in antagonizing the cytotoxic effects of 0.3 mM CldU. CldU appears to cause cytotoxicity by at least two mechanisms, only one of which was reversible by dC. Because the addition of dC to HL-60 cells could only partially rescue the cells from dT (or dG) inhibition, Ross et al. (40) concluded that these nucleosides act at sites other than ribonucleotide reductase to inhibit colony formation. Cellular uptake, phosphorylation, and polymerization could also be affected. The same considerations are appropriate regarding inhibition by CldU in the present studies; in addition, CldU incorporation into DNA may result in toxicity because of impairment of replication or transcription. Only a small component of this portion of the toxicity would be affected by administration of dC.
A priori, it was thought that the use of 2'-dH4U would help elucidate whether dC antagonism of CldU toxicity is due to replenishing low dCTP pools or to a more direct antagonism by TTP, derived from dC, against CIdUTP. The situation is more complex and can only be fully interpretated with associated biochemical studies ( (Fig. 5) . Increasing the H4U concentrations to levels found to completely eliminate cytotoxicity in the presence of dC (see Fig. 2) did not alter the antiviral effect either with or without dC (Fig. 6) . Unlike the antagonism by dC of CldC cytotoxicity without an altered antiviral effect, inclusion of dT completely eliminated the antiherpetic activity of CldC, leaving only that decrease in HSV-2 titer characteristic of dT itself (Fig. 7) . dT antagonized the cytotoxicity of high concentrations of CldC (Fig. 8) .
The dramatic display of the antagonism of the antiviral activity of CldC by dT summarized in Fig. 7 also serves to dispel arguments that the selective antagonism is merely a matter of resolution, since the antagonism of cytotoxicity is depicted in an arithmetic plot, whereas the absence of significant antagonism of the antiviral activity by dC is depicted in a logarithmic plot. These results also indicate that in HSV-2-infected cells, in the presence of CldC (and H4U), dC is not efficiently converted to thymidine or its aq;bolites. (Table 2) . Results similar to those shown with HSV-1 strain F were obtained with HSV-1 strain McKrae and HSV-1 strain Shealy. A simple interpretation of these results is that CldC is not as readily phosphorylated by the HSV-1 pyrimidine nucleoside kinase as it is by that of HSV-2, whereas CldU is phosphorylated to a similar extent in HSV-1-and HSV-2-infected cells.
In vivo studies. The in vitro studies were sufficiently encouraging to warrant an in vivo trial with the hairless mouse topical infection system with HSV-2, even though the limited supply of CldC precluded an extensive study. Nineteen hairless mice, weighing 22 to 28 g each, were inoculated with HSV-2 as described in Materials and Methods. The following day, they were randomly divided into three groups; nine were mock treated, and two groups of five were treated with 5 mmol of H4U per kg in 0.3 ml of PBS, followed 0.5 h later by either 20 mmol of CldC per kg or 20 mmol of CldC plus 5 mmol of dC per kg in 0.8 ml of PBS for 8 VOL. 22, 1982 CldC (0.3 mM) + H4U (500 Fg/ml) 31 -2.7 -1.4 CldC (0.3 mM) + 2'-dH4U (500 Fig/ml) 59
consecutive days. The mortality data (Fig. 9A) indicates a delay in time of death when animals were treated without dC and an increase in both time of survival and numbers of survivors when dC was added to the treatment regimen. The morbidity data in CldU, the deaminated form of CldC, was studied to eliminate both the issues of competition for the deaminases and for dC kinase from consideration since CldU is anabolized via dT kinase, for which dC is not a substrate. dC was found to reverse both the premitotic arrest and the inhibition of colony-forming ability caused by low (0.015 mM) but not high (0.3 mM) concentrations of CldU. In the latter case, addition of dC to incubations allowed the treated cells to progress further in the cell cycle, but not to successfully undergo mitosis.
Although no nucleoside analog has yet been shown to exert an antiherpetic effect without incorporation into viral DNA, it seems clear that cytotoxicity may result from additional mechanisms. High doses of dT induce a block in DNA synthesis that can be reversed equally well by reducing the dT content of the medium or by adding dC (44) . The dT analog BrdU is similarly cytotoxic, apparently through inhibition of ribonucleoside diphosphate reductase; indeed, the inhibition is even more extensive with BrdU than with dT (34) . The inhibition chiefly affects the reduction of CDP and UDP to deoxynucleotides, and cytotoxicity is a result of depletion of dCTP pools, which are intrinsically low. Coadministration of BrdU and dC has been suggested in certain systems to reduce cytotoxicity without reduction of incorporation of BrdU into DNA (4, 30) , apparently by circumventing the inhibition of ribonucleoside diphosphate reductase, supplying dCDP by the salvage pathway instead. These investigators did not utilize H4U, but they did utilize 5-flourodeoxyuridine (with dC and BrdU) to inhibit thymidylate synthetase, so that dC, even though deaminated to ultimately form dUMP, could not readily serve as a source of TMP.
The studies of Ashman and Davidson (2) on mutagenesis may suggest another minor mechanism of dC antagonism. In those and other studies (1, 28) , it was demonstrated that mutagenesis was dependent on the BrdUTP/dCTP ratio and not on the extent of incorporation of BrdU into DNA. If a portion of the toxicity was due to CldUTP acting as CldCTP, pairing with guanine residues in DNA due to tautomeric shifts, then dCTP would antagonize a portion of the toxicity as it antagonizes mutagenesis.
In contrast to the mammalian ribonucleotide reductase, both HSV-1 and HSV-2 encode a reductase that is refractory to inhibition by TTP (13, 36) . Thus, HSV-1 can replicate even in cells inhibited by excess dT (12) , and although HSV-2 is inhibited by dT, this inhibition does not involve nucleoside diphosphate reductase (39) and the inhibition is not reversed by dC (29) . Therefore, any nucleoside analog whose cytotoxicity was at least partly due to ribonucleoside diphosphate reductase inhibition would be rendered less toxic by administration of dC without diminishing its antiherpetic effect.
One may question the role of the reductase for HSV replication in view of the importance of the salvage rather than the de novo pathway in virus synthesis. Inhibition of thymidylate synthetase has no effect on virus titers, whereas thymidine kinase-negative HSV mutants are adversely affected in serum-depleted medium. On the other hand, hydroxyurea, an inhibitor of ribonucleoside reductase, also inhibits HSV replication (17, 42) . One can speculate that the enzyme is involved in the synthesis of a deoxyribonucleoside triphosphate that will serve as a physiologically effective phosphate donor for the nucleoside kinases of the salvage pathway. Dobersen and Greer (20) , for example, found that dCTP was an effective phosphate donor for the phosphorylation of dT by the HSV-2 pyrimidine nucleoside kinase. Deoxyribonucleotide triphosphates may also be essential effectors for control purposes to shut off enzymes necessary for host DNA synthesis, such as host ribonucleotide reductase or dCMP deaminase, as suggested ny VOL. 22, 1982 Jamieson and Bjursell (25, 26) . High levels of dTTP, which have been found in HSV-infected cells (9, 26) , may play a role in increasing the levels of dGTP in HSV-infected cells by shifting the substrate specificity of ribonucleotide diphosphate reductase towards the production of dGTP, as Ponce de Leon et al. (36) have suggested. dGTP levels are low in uninfected cells but elevated in infected cells, presumably to meet the demands for extensive DNA synthesis.
A minor factor that may contribute to the selective antagonism is related to the insensitivity of the HSV pyrimidine nucleoside kinase to end product inhibition by dCTP, as described by Doberson and Greer (20) . dC kinase of uninfected cells, in contrast, is end product inhibited by dCTP (16) . This means that in the uninfected cell, addition of dC will eventually result in inhibition of the enzyme (dC kinase) capable of converting (though poorly) 5-halo dC into 5-halo dCMP. This should prevent toxicity, whereas the viral pyrimidine nucleoside kinase will continue phosphorylating 5-halo dC to an antiviral nucleotide regardless of the levels of dCTP.
The paramount basis for the selective antagonism resides in the differences in Kms of host and viral enzyme for substrates and antagonists and may also be due to the fact that the antiviral effect is due to incorporation of 5-halo dU analogs into DNA, an effect not antagonized by dC, whereas the cytotoxic effect may reside in the sensitivity of ribonucleoside reductase to 5-halo dUTP in infected cells, an inhibition that is antagonized by dC.
Renis (37) reported that both the cytotoxicity and antiherpetic activity of 1-P3-D-arabinofuranosyl-5-iodocytosine was antagonized by dC, whereas thymidine and uridine antagonized the antiviral effect without affecting cytotoxicity. For purposes of comparison with ara-IC, Renis observed that the antiviral effect of IdC was antagonized by thymidine and not by dC. The thrust of the paper, however, was on ara-IC, and neither cytotoxicity studies with IdC were undertaken nor was there any further comment on the significance of this observation. It was not until the studies of Meuth and Green (34) on the basis of the cytotoxicity of 5-halo dUTP and the kinetic studies from this laboratory (cited above) and from that of Cheng (6) and Cheng and Ostrander (11) on viral and host enzymes, that this unheralded observation could be considered in terms of heightened efficacy in HSV infections.
It would be important to determine whether the principles of selective antagonism encountered in this study can be exploited in antimetabolite chemotherapy of bacterial, parasitic, and neoplastic diseases as well as against viral infections.
